Influenza Surveillance at IRID Immunization and Respiratory Infections Division Centre for...

24
Influenza Surveillance at IRID Immunization and Respiratory Infections Division Centre for Infectious Disease Prevention & Control Public Health Agency of Canada

Transcript of Influenza Surveillance at IRID Immunization and Respiratory Infections Division Centre for...

Influenza Surveillanceat IRID

Immunization and Respiratory Infections DivisionCentre for Infectious Disease Prevention & Control

Public Health Agency of Canada

Impact of InfluenzaIn Canada: • 10-25% of population affected yearly (higher

infection rates in children and elderly)• 70-75,000 hospitalizations• 6-7,000 deaths due to pneumonia and influenza• 500-1,500 deaths due to influenza

0

2000

4000

6000

8000

10000

12000

14000

1992

01

1993

01

1994

01

1995

01

1996

01

1997

01

1998

01

1999

01Year & Month

P&I Morbidity

Canada’s National Influenza Surveillance Program

Primary Objectives : 1) Early detection and monitoring of influenza outbreaks

2) Provide timely and up-to-date reporting of influenza activity in Canada and abroad to professionals & public

3) Monitor circulating strains of influenza virus, including new sub-types

4) Contribute to the information for vaccine composition for following season

Influenza Surveillance

ILI ConsultationsSentinel Physicians

Laboratories Number of Influenza tests and positives

National Microbiology Laboratory

Strain Characterization

Provincial/Territorial Epidemiologists

Influenza activity levels (outbreaks etc)

Data Provider Indicator

Uses of Surveillance Data

• estimating disease impact – influenza-like illness clinic visits– influenza and pneumonia

hospitalizations and deaths– all cause mortality– other health and economic impacts

• monitoring viral evolution – identification of predominant strains– detection of new strains/subtypes

Influenza prevention and control policies

Vaccine composition program development and timing

Number of Influenza regions reporting widespread or localized activity

0

5

10

15

20

25

30

8-30

9-13

9-27

10-1

1

10-2

5

11-8

11-2

2

12-6

12-2

0

1-3

1-17

1-31

2-14

2-28

3-13

3-27

4-10

4-24 5-

8

5-22 6-

5

6-19 7-

3

7-17

7-31

8-14

2003 Report week ending 2004

Number of regions

Localized activity Widespread activity

0

100

200

300

400

500

600

700

800

900

1000

35 41 47 53 6 12 18 43 49 3 9 15 21 37 43 49 3 9 15 21 27 35 41 47 1 7 13 19 25 39 45 51 5 11 17 23 29 35 36 42 48 2 8 14 20 26 32 39 45 51 5 11 17 23 29 35

Nu

mb

er

of

Ca

se

s /

No

mb

re d

e c

as

Influenza A

Influenza B

Week Influenza Season 1997/98 1998/99 1999-2000 2000/01 2001/02 2002/03 2003/04

Predominant strain(s)/ viruses similar to/ viruses similar to/ viruses similar to/ viruses similar to/ viruses similar to/ viruses similar to/ viruses similar to/

Souche(s) Analogues à : Analogues à : Analogues à : Analogues à : Analogues à : Analogues à : Analogues à :prédominante(s) A/Sydney/5/97(H3N2) A/Sydney/5/97(H3N2) A/Sydney/5/97(H3N2) A/NewCaledonia/20/99- A/Panama/2007/99 (H3N2) A/(H1N2) A/Fujian/411/02 (H3N2) B/Beijing/184/93 B/Beijing/184/93 (H1N1) A/H1N2 B/Hong Kong/330/01

Seasonal Distributuion of Laboratory Confirmed Influenza Infections by influenza type, Canada 1997-2004

Influenza Tests, % positive, & ILI rates, Canada, by report week, 2003-2004

0

500

1000

1500

2000

2500

3000

3500

4000

4500

8-30

9-13

9-27

10-1

1

10-2

5

11-8

11-2

2

12-6

12-2

0

1-3

1-17

1-31

2-14

2-28

3-13

3-27

4-10

4-24 5-

8

5-22 6-

5

6-19 7-

3

7-17

7-31

8-14

2003 Report week ending 2004

Number of tests

0

10

20

30

40

50

60

70

80

% Positive

Number of tests % Positive ILI Rate

Proportion of lab-confirmed influenza by age-group, Canada, 2003-2004

Age unknown1%

<5 years33%

5-9 years5%

10-14 years5%

15-24 years11%

25-44 years11%

45-64 years9%

65 years25%

Influenza Strain Identification

B/ Sichuan/ 379/ 99-like [33]

H1N2[1]

A/ Panama/ 2007/ 99 (H3N2)-like

[25]

A/ Fujian/ 411/ 02-like (H3N2) [776]

A/ New Caledonia/ 20/ 99-

like (H1N1) [3]

B/ Hong Kong/ 330/ 01-like

[7]

Influenza Activity Level by Provincial and Territorial Influenza Surveillance Regions, Canada,

Week 03 2004

FluWatch on the Webhttp://www.phac-aspc.gc.ca/fluwatch/index.html

New Initiatives….• Impact of influenza in children -

hospitalizations • Sentinel hospital-based surveillance• Trained nurse monitor at each centre

identifies eligible cases and completes detailed case report forms Admissions by Age-group

2004-05

29%

30%

19%

14%

8%

0-5 months

6-23 months

2-4 years

5-9 years

10-16 years

New Initiatives..

Canadian Network for Public Health Intelligence (CNPHI)

• CNPHI is a secure internet-based suite of applications and resources.

• It is primarily directed towards strategic public health information and intelligence sharing.

• Included applications: – Atlantic Canada FluWatch Application – Canadian Integrated Outbreak Surveillance Centre

(CIOSC).

New Initiatives: CNPHI

Canadian Integrated Outbreak Surveillance Centre (CIOSC)

Canadian Integrated Outbreak Surveillance Centre (CIOSC)

• Goal: To enhance public health’s capacity to anticipate and detect health risks associated with communicable disease threats.

SRI Alerts: An SRI alert is an operational definition used to ensure that individuals meeting specific criteria are identified in a systematic way to allow for implementation of appropriate infection control and public health measures until SARS or other emerging respiratory pathogen has been ruled out as a cause of the illness

Severe Respiratory Illness (SRI) Surveillance

SRI Alerts

An SRI alert is sent under the following situations:

• An individual is hospitalized with an SRI and has a potential epidemiologic link to a source of emerging respiratory pathogen

• Clusters of SRI are identified within a health care unit

• An individual has been identified with laboratory evidence of a SARS-CoV infection (or other emerging respiratory infection)

• An individual has been identified with a laboratory confirmed influenza A/ H5N1 or other novel influenza virus infection